Leukemia research, 2023-08, Vol.131, p.107331-107331, Article 107331
2023
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Outcomes with molecularly targeted agents as salvage therapy following frontline venetoclax + hypomethylating agent in adults with acute myeloid leukemia: A multicenter retrospective analysis
- Ist Teil von
- Leukemia research, 2023-08, Vol.131, p.107331-107331, Article 107331
- Ort / Verlag
- England: Elsevier Ltd
- Erscheinungsjahr
- 2023
- Quelle
- MEDLINE
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0145-2126eISSN: 1873-5835DOI: 10.1016/j.leukres.2023.107331Titel-ID: cdi_proquest_miscellaneous_2822378127
- Format
- –
- Schlagworte
- Acute myeloid leukemia, Adult, AML, Antineoplastic Agents - therapeutic use, Antineoplastic Combined Chemotherapy Protocols - therapeutic use, Bridged Bicyclo Compounds, Heterocyclic - therapeutic use, Enasidenib, Gilteritinib, HMA, Humans, Hypomethylating agents, Ivosidenib, Leukemia, Myeloid, Acute - drug therapy, Leukemia, Myeloid, Acute - genetics, Outcomes, Salvage Therapy, Targeted therapies, Venetoclax